Impaired interleukin-10 production in response to CpG and depletion of the regulatory CD19+CD24hiCD38hi B cell compartment in patients with coronary atherosclerosis by Dumitriu, IE et al.
Impaired interleukin-10 production in response to CpG and depletion of 
the regulatory CD19+CD24hiCD38hi B cell compartment in patients with 
coronary atherosclerosis 
 
I. E. Dumitriu, P. Baruah, S. Dinkla, J. Bullenkamp and J. C. Kaski  
 
Background/Introduction: B-lymphocytes have critical roles in the 
inflammatory process that drives atherosclerosis. In animal models, 
conventional B2 B cells promote atherosclerosis, whilst innate B1a B cells are 
protective. B cells with regulatory function (Bregs) have been identified in 
animals and humans and have been implicated in the pathogenesis of 
autoimmunity. Whether Bregs have a role in human atherosclerosis is 
currently unknown.  
Purpose: Our aim was to characterise the frequency, phenotype and function 
of Bregs in atherosclerosis patients. 
Methods: CD19+CD24hiCD38hi Bregs were quantified in patients with 
atherosclerosis (myocardial infarction (MI), n=60; stable angina, SA, n=40), 
and in healthy subjects (n=30) using flow cytometry. Interleukin-10 (IL-10) 
production was quantified by intracellular staining. 
Results: The percentage and absolute number of circulating Bregs were 
markedly reduced in MI and SA patients compared to healthy subjects. No 
differences were noted in total, mature or memory B cells, suggesting a 
specific depletion of the Breg cell subset. Bregs from MI and SA patients 
produced significantly less IL-10 in response to CpG but not CD40L compared 
to Bregs from healthy subjects. IL-10 production by mature and memory B 
cells was not impaired. Molecular mechanisms that underlie defects in Bregs 
in patients with atherosclerosis are being characterised. 
Conclusions: Our data show for the first time that patients with 
atherosclerosis harbour marked numerical and functional defects in Breg cells 
that may tip the balance in favour of pro-inflammatory B and T lymphocytes. A 
better understanding of these defects may reveal novel targets for therapies 
to tackle inflammation in atherosclerosis. 
